The Business Times
business-time-50

US FDA authorises Moderna, Pfizer updated Covid boosters for 6 months old

google-preferred-sourceAdd BT as a preferred source
Published Thu, Dec 8, 2022 · 11:30 PM
    • The FDA authorisations allow use of Moderna’s bivalent shot in children 6 months through 5 years of age, while the Pfizer/BioNTech vaccine can be given to those aged 6 months through 4 years.
    • The FDA authorisations allow use of Moderna’s bivalent shot in children 6 months through 5 years of age, while the Pfizer/BioNTech vaccine can be given to those aged 6 months through 4 years. PHOTO: REUTERS

    THE US Food and Drug Administration on Thursday (Dec 8) authorised updated Covid-19 booster shots from Moderna and Pfizer and its partner BioNTech for children as young as 6 months of age.

    The amended authorisations allow use of Moderna’s bivalent shot in children 6 months through 5 years of age, while the Pfizer/BioNTech vaccine can be given to those aged 6 months through 4 years.

    Pfizer’s shot can be administered as the third shot for those eligible and have not completed their primary vaccination series, the agency added. REUTERS

    Decoding Asia newsletter: your guide to navigating Asia in a new global order. Sign up here to get Decoding Asia newsletter. Delivered to your inbox. Free.

    ModernaPfizerCovid-19United States

    Share with us your feedback on BT's products and services

    Feedback

    TRENDING NOW

    Yeoh Pei Xien is the youngest grandchild of Yeoh Tiong Lay, who founded Malaysian multinational conglomerate YTL Corporation.

    Yeoh Pei Xien: YTL’s third-gen scion with a pastor’s heart

    Grant Wee built Hideaway as a massage-and-bathhouse concept centred on solitude and recovery.

    UOB CEO’s youngest child Grant Wee turns burnout into a wellness business

    Keppel declares an interim cash dividend of S$0.15 per share for H1 2026, unchanged from the year-ago period.

    Keppel H1 net profit drops 59% to S$155 million on impairments, M1 deal fallout; shares fall 4%

    Singtel says both options remain at an exploratory level for now.

    Singtel explores Nasdaq-SGX dual listing for data centre arm Nxera, local data centre Reit

    Latest T-bills Treasury Bills Results & Interest NewsLatest SSB Singapore Savings Bonds NewsLatest COE Certificate of Entitlement News
    Latest Johor-Singapore SEZ NewsLatest BTO Build To Order & Sales of Balance NewsLatest STI Straits Times Index NewsLatest SGX Dividends, Share Price NewsLatest Bonds Market NewsLatest Singapore Stocks To Buy NewsLatest Singapore Economy News
    View More